Neurosurgical Resection of Multiple Brain Metastases: Outcomes, Complications, and Survival Rates in a Retrospective Analysis

Overview

Journal J Neurooncol

Publisher Springer

Date 2024 Jun 21

PMID 38904924

Authors

Sebastian Niedermeyer

M Schmutzer-Sondergeld

J Weller

S Katzendobler

S Kirchleitner

R Forbrig

P N Harter

L V Baumgarten

C Schichor

V Stoecklein

N Thon

Affiliations

Soon will be listed here.

Abstract

Purpose: This study investigates the outcomes of microsurgical resection of multiple brain metastasis (BMs).

Methods: This retrospective, monocentric analysis included clinical data from all consecutive BM patients, who underwent simultaneous resection of ≥ 2 BMs between January 2018 and May 2023. Postoperative neurological and functional outcomes, along with perioperative complications, as well as survival data were evaluated.

Results: A total of 47 patients, with a median age of 61 years (IQR 48-69), underwent 73 craniotomies (median 2; range 1-3) for resection of 104 BMs. Among patients, 80.8% presented with symptomatic BMs, causing focal neurological deficits in 53% of cases. Gross total resection was achieved in 87.2% of BMs. Karnofsky Performance Scale (KPS) scores improved in 42.6% of patients, remained unchanged in 46.8%, and worsened in 10.6% after surgery. Perioperative complications were observed in 29.8% of cases, with transient complications occurring in 19.2% and permanent deficits in 10.6%. The 30-days mortality rate was 2.1%. Logistic regression identified eloquent localization (p = 0.036) and infratentorial craniotomy (p = 0.018) as significant predictors of postoperative complications. Concerning overall prognosis, patients with permanent neurological deficits post-surgery (HR 11.34, p = 0.007) or progressive extracranial disease (HR: 4.649; p = 0.006) exhibited inferior survival.

Conclusion: Microsurgical resection of multiple BMs leads to clinical stabilization or functional improvement in most patients. Although transient complications do not affect overall survival, the presence of persistent neurological deficits (> 3 months post-surgery) and progressive extracranial disease negatively impact overall survival. This highlights the importance of careful patient selection for resection of multiple BMs.

References

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

Junger S, Pennig L, Schodel P, Goldbrunner R, Friker L, Kocher M . The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting. Cancers (Basel). 2021; 13(6). PMC: 8004079. DOI: 10.3390/cancers13061435. View

Mintz A, Kestle J, Rathbone M, Gaspar L, Hugenholtz H, Fisher B . A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996; 78(7):1470-6. DOI: 10.1002/(sici)1097-0142(19961001)78:7<1470::aid-cncr14>3.0.co;2-x. View

Valiente M, Ahluwalia M, Boire A, Brastianos P, Goldberg S, Lee E . The Evolving Landscape of Brain Metastasis. Trends Cancer. 2018; 4(3):176-196. PMC: 6602095. DOI: 10.1016/j.trecan.2018.01.003. View

Stelzer K . Epidemiology and prognosis of brain metastases. Surg Neurol Int. 2013; 4(Suppl 4):S192-202. PMC: 3656565. DOI: 10.4103/2152-7806.111296. View

Xue Q . The frailty syndrome: definition and natural history. Clin Geriatr Med. 2010; 27(1):1-15. PMC: 3028599. DOI: 10.1016/j.cger.2010.08.009. View

Mok T, Wu Y, Ahn M, Garassino M, Kim H, Ramalingam S . Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2016; 376(7):629-640. PMC: 6762027. DOI: 10.1056/NEJMoa1612674. View

Hatiboglu M, Akdur K, Sawaya R . Neurosurgical management of patients with brain metastasis. Neurosurg Rev. 2018; 43(2):483-495. DOI: 10.1007/s10143-018-1013-6. View

Colasacco C, Abouezzi J, Arbuiso S, Asserson D, Kazim S, Cole K . Association of baseline frailty and age with postoperative outcomes in metastatic brain tumor patients. J Neurosurg Sci. 2022; 68(5):526-532. DOI: 10.23736/S0390-5616.22.05865-9. View

10.

Kalkanis S, Kondziolka D, Gaspar L, Burri S, Asher A, Cobbs C . The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2009; 96(1):33-43. PMC: 2808516. DOI: 10.1007/s11060-009-0061-8. View

11.

Hadi I, Roengvoraphoj O, Bodensohn R, Hofmaier J, Niyazi M, Belka C . Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis. Radiat Oncol. 2020; 15(1):37. PMC: 7023694. DOI: 10.1186/s13014-020-1485-8. View

12.

Pollock B, Brown P, Foote R, Stafford S, Schomberg P . Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neurooncol. 2003; 61(1):73-80. DOI: 10.1023/a:1021262218151. View

13.

Fecci P, Champion C, Hoj J, McKernan C, Goodwin C, Kirkpatrick J . The Evolving Modern Management of Brain Metastasis. Clin Cancer Res. 2019; 25(22):6570-6580. PMC: 8258430. DOI: 10.1158/1078-0432.CCR-18-1624. View

14.

Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R . A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322(8):494-500. DOI: 10.1056/NEJM199002223220802. View

15.

Karschnia P, Vogelbaum M, van den Bent M, Cahill D, Bello L, Narita Y . Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021; 149:23-33. DOI: 10.1016/j.ejca.2021.03.002. View

16.

Lagerwaard F, Levendag P, Nowak P, Eijkenboom W, Hanssens P, Schmitz P . Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999; 43(4):795-803. DOI: 10.1016/s0360-3016(98)00442-8. View

17.

Dicpinigaitis A, Hanft S, Cooper J, Gandhi C, Kazim S, Schmidt M . Comparative associations of baseline frailty status and age with postoperative mortality and duration of hospital stay following metastatic brain tumor resection. Clin Exp Metastasis. 2022; 39(2):303-310. DOI: 10.1007/s10585-021-10138-3. View

18.

Mancuso A, Vedovati M, Pierpaoli L, Paliani U, Conti S, Filippucci E . PO-40 - Real-life use of non-vitamin k antagonist oral anticoagulants in patients with cancer associated venous thromboembolism: data from a prospective cohort. Thromb Res. 2016; 140 Suppl 1:S191. DOI: 10.1016/S0049-3848(16)30173-6. View

19.

Rick J, Shahin M, Chandra A, Dalle Ore C, Yue J, Nguyen A . Systemic therapy for brain metastases. Crit Rev Oncol Hematol. 2019; 142:44-50. PMC: 6746616. DOI: 10.1016/j.critrevonc.2019.07.012. View

20.

Agnoletti A, Mencarani C, Panciani P, Buffoni L, Ronchetti G, Spena G . Surgery in cerebral metastases: are numbers so important?. J Cancer Res Ther. 2014; 10(1):79-83. DOI: 10.4103/0973-1482.131390. View